Get the Stockscreener App
85.60
0.81%
-0.70
After Hours:
85.73
0.13
+0.15%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $85.60, with a volume of 21.13M.
It is down -0.81% in the last 24 hours and down -6.27% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$86.30
Open:
$86.65
24h Volume:
21.13M
Relative Volume:
1.73
Market Cap:
$149.10B
Revenue:
$45.13B
Net Income/Loss:
$6.28B
P/E Ratio:
23.85
EPS:
3.5895
Net Cash Flow:
$7.38B
1W Performance:
-2.07%
1M Performance:
-6.27%
6M Performance:
-33.59%
1Y Performance:
-35.57%
1-Day Range:
$85.28
$86.73
1-Week Range:
$84.96
$86.96
52-Week Range:
$81.97
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
85.60 | 150.32B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
305.09 | 117.93B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
73.81 | 97.02B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
48.31 | 72.99B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.47 | 49.50B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Is ACS’s Cologuard Endorsement Reshaping the Investment Case for Abbott Laboratories (ABT)? - Yahoo Finance
Piper Sandler Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $115 - 富途牛牛
BSX vs. ABT: Which Medical Stock Has More Upside Potential? - TradingView
Is Abbott Laboratories Stock Underperforming the Dow? - Yahoo Finance
Abbott gets European OK to market world’s first dual glucose-ketone sensor - Crain's Chicago Business
A Look At Abbott Laboratories (ABT) Valuation After New Approvals For Libre Duo And Ultreon 3.0 - simplywall.st
Abbott Laboratories stock (US0028241000): focus on valuation as regulatory AI approvals frame growth - AD HOC NEWS
Abbott Labs Settles Ill. Genetic Privacy Suit - Law360
Abbott Laboratories stock (US0028241000): regulatory clearances for AI cardiology and glucose-ketone - AD HOC NEWS
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views? - Yahoo Finance
Abbott obtains CE mark for duo of glucose-ketone monitors - Yahoo Finance
Abbott Clears AI Cardiology And Dual Sensors As Shares Face Pressure - simplywall.st
Abbott (ABT) Wins FDA and EU Approval for an AI-Powered Tool That Guides Artery Stent Placement - Insider Monkey
Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance Singapore
10 Dividend Growth Stocks To Guard Wealth - Sure Dividend
Abbott Labs Settles Illinois Medical History Privacy Lawsuit - Bloomberg Law News
Abbott (ABT) Launches Innovative Dual Glucose-Ketone Monitoring System - GuruFocus
Abbott secures CE mark for dual glucose-ketone sensing technology for diabetes patients - marketscreener.com
Abbott Laboratories stock (US0028241000): investors weigh diagnostics and growth drivers - AD HOC NEWS
Abbott secures CE mark for dual glucose-ketone sensor By Investing.com - Investing.com Canada
Abbott wins CE mark for dual glucose-ketone sensor - Drug Delivery Business
New Abbott sensor tracks glucose and ketones to flag DKA risk - Stock Titan
How Abbott's Diagnostics Unit Is Shaping Up Through the Rest of 2026 - Yahoo! Finance Canada
Abbott (ABT) Sees Cologuard and Cologuard Plus Confirmed in Upda - GuruFocus
ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening - PR Newswire
Abbott Laboratories stock (US0028241000): investors weigh diagnostics strength and medical-device he - AD HOC NEWS
Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026 - PR Newswire
Abbott Laboratories (ABT) Slid on Headwinds in Nutrition Business - Insider Monkey
Why Johnson & Johnson Might Be the Smartest Dividend King to Buy in Today's Market - The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Abbott Laboratories (ABT) Stock Analysis: Tapping Into A 35.73% Potential Upside - DirectorsTalk Interviews
Reassessing Abbott Laboratories (ABT) After A 32% One Year Share Price Decline - Yahoo Finance
Abbott Deepens Digital Health Push With New Cardiovascular Diagnostics And Wearables - simplywall.st
Abbott Laboratories stock is getting decimated, but the smart money senses opportunity - MSN
Abbott Laboratories Stock Is Getting Decimated, But the Smart Money Senses Opportunity - Barchart.com
Has the Abbott Laboratories Sell-Off Finally Created an Entry Point? - AOL.com
Abbott Laboratories (ABT) Slid Due To Its Nutrition Segment’s Sensitivity to Consumer Spending Momentum - Insider Monkey
Waiting on Integration Result, Market Stays Moderated on Abbott Laboratories (ABT) - Insider Monkey
Three Recession-Resistant Stocks Worth Investors’ Attention - NAI500
Abbott’s Lingo Wearable And Cardio R&D Reframe Long Term Growth Story - Yahoo Finance
Abbott Laboratories, Coca-Cola, and Walmart: Top Recession-Proof Stocks for 2026News and Statistics - IndexBox
ABT Stock Chart | ABBOTT LABORATORIES (NYSE:ABT) - ChartMill
Abbott Laboratories cuts outlook, says mild flu season hurt sales - MSN
Has the Abbott Laboratories sell-off finally created an entry point? - MSN
Long term debt to total equity ratio of Abbott Laboratories – BVL:ABTUS - TradingView
Abbott Laboratories Balance Sheet – BVL:ABTUS - TradingView
NEC Baby Formula Lawsuit & Settlement | May 2026 Update - Lawsuit Information Center
Buying pulsed field ablation systems: What hospitals should know - Modern Healthcare
3 Stocks to Buy if You Think the Economy Is Heading for a Recession - The Motley Fool
Abbott Laboratories stock (US0028241000): diabetes business and latest earnings in focus - AD HOC NEWS
Abbott Laboratories stock (US0028241000): investors eye upcoming Q4 2025 earnings call and biosimila - AD HOC NEWS
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.83%
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):